1-3 of 3
John Fry
Close
Sort by
Journal Articles

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Clinical Trials & Observations
Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal
Journal: Blood
Blood (2012) 120 (3): 552–559.
https://doi.org/10.1182/blood-2011-06-360552
Published: 2012
Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2010) 116 (21): 986.
https://doi.org/10.1182/blood.V116.21.986.986
Published: 2010
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath
Journal: Blood
Blood (2009) 114 (22): 432.
https://doi.org/10.1182/blood.V114.22.432.432
Published: 2009